FAB — Fusion Antibodies Income Statement
0.000.00%
Last trade - 00:00- £7.71m
- £7.30m
- £1.14m
Annual income statement for Fusion Antibodies, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.9 | 4.17 | 4.8 | 2.9 | 1.14 |
| Cost of Revenue | |||||
| Gross Profit | 1.77 | 2.02 | 2.47 | 0.574 | -0.045 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.95 | 5.41 | 6.12 | 5.76 | 3.42 |
| Operating Profit | -1.06 | -1.25 | -1.32 | -2.86 | -2.29 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.07 | -1.26 | -1.33 | -2.86 | -2.29 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.697 | -2.9 | -1.2 | -2.6 | -2.23 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.697 | -2.9 | -1.2 | -2.6 | -2.23 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -0.697 | -2.9 | -1.2 | -2.6 | -2.23 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.032 | -0.114 | -0.046 | -0.1 | -0.04 |